CN106053843A - Lip cancer specificity detection kit - Google Patents

Lip cancer specificity detection kit Download PDF

Info

Publication number
CN106053843A
CN106053843A CN201610623977.8A CN201610623977A CN106053843A CN 106053843 A CN106053843 A CN 106053843A CN 201610623977 A CN201610623977 A CN 201610623977A CN 106053843 A CN106053843 A CN 106053843A
Authority
CN
China
Prior art keywords
crisp1
aptamer
lip cancer
dna
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201610623977.8A
Other languages
Chinese (zh)
Inventor
陈博
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN201610623977.8A priority Critical patent/CN106053843A/en
Publication of CN106053843A publication Critical patent/CN106053843A/en
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4746—Cancer-associated SCM-recognition factor, CRISPP
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/18—Dental and oral disorders

Abstract

The invention discloses a lip cancer specificity detection kit. The aptamer provided by the invention has good affinity with human cysteine-rich secretory protein 1. By utilizing the aptamer provided by the invention, the protein of the cysteine-rich secretory protein 1 in saliva can be captured; lip cancer is detected through the change of the protein content of the cysteine-rich secretory protein 1; the aptamer is prepared into a corresponding kit which is used for screening the lip cancer. The kit disclosed by the invention has the advantages of high sensitivity and low cost.

Description

A kind of test kit of lip cancer specific detection
Technical field
The present invention relates to a kind of test kit for detecting lip cancer and detection method thereof.
Background technology
Lip cancer refers to that the malignant tumor betiding upper and lower lip is one of oral cavity common cancer, accounts in oral cancer Vertical position, accounts for the 0.1%～0.5% of whole body malignant tumor, accounts for the 7.1%～15.0% of malignant tumor of mouth, American-European countries's lip cancer Patient is more, accounts for the 20%～30% of oral cancer.Typically lower lip is easier than upper lip gets involved, and about 90%～95% occurs at vermilion border of lower lip Portion, and be common at outer the 1/3 of W lower lip.Male patient is in the majority, and the ratio of men and women is 7:1.Age occurred frequently is 50～70 years old.Lip The cancer overwhelming majority is the shape cell carcinoma of differentiated, how to occur on the basis of the optimum pathological changes taking biology, and its speed of growth is relatively slow, Prognosis is preferable, and within general 5 years, survival rate is on 70%W, and the cause of disease of primary disease may be stimulated by foreign body for a long time with local, strong ultraviolet Line irradiates relevant.Lip epithelium keratinization, white macula, skilful expense, granuloma and breach etc. are not healed for a long time, also may result in canceration.
Known in the art, saliva is that 10-40ng can be diagnosed as lip cancer rich in hemiamic acid secretory protein 1 concentration.Cause This, the concentration of detection hemiamic acid secretory protein 1 becomes particularly important.
Aptamer (Aptamer, also known as aptamers, aptamer) is can high-affinity, certain life of combination of high specific Thing leather El target strand widow's nucleic acid molecules (ssDNA or ssRNA).Aptamer is by index concentration Fas lignand system evolution technology (Systematlc Evolutlon of Llgands by Exponentlal enrlchment, SELEX) is from synthetic What in DNA/RNA library, screening obtained can combine the single stranded DNA/RNA of target molecules by high degree of specificity.Report aptamer Target include metal ion, organic molecule, polypeptide, protein, cell even tissue etc..The molecular recognition merit of aptamer Can be similar with antibody, there is the target identification ability the most higher with antibody molecule, but have the most excellent compared with antibody Good characteristic, as molecular weight is little, can manufacture, not easy in inactivation, non-immunogenicity, be readily synthesized with labelling, quickly penetrate Between tissue, good dynamic metabolism, different batches, product does not haves difference and has fine chemical stability, at biology The fields such as detection, medical diagnosis on disease treatment have important application prospect.
Summary of the invention
It is an object of the invention to provide aptamer and the test kit thereof of a kind of specific bond CRISP1.
The aptamer that the present invention provides, is the single stranded DNA shown in sequence 1-15 of sequence table.
Described aptamer and CRISP1 albumen have preferable affinity.
Also described aptamer can be modified or transformed, obtain the derivant of described aptamer.
The derivant of described aptamer can be following any one:
A) described aptamer being deleted part or increases the nucleotide of partial complementarity, obtain has with described aptamer There is the derivant of the aptamer of identical function；
B) described aptamer carrying out nucleotide replacement or part is modified, obtain has identical with described aptamer The derivant of the aptamer of function；
C) transforming the skeleton of described aptamer as phosphorothioate backbone, obtain has phase with described aptamer The derivant of the aptamer of congenerous；
D) aptamer transform peptide nucleic acid(PNA) as, obtain has the aptamer of identical function with described aptamer Derivant；
E) after described aptamer being connected upper fluorescence, radioactivity and therapeutic substance, that obtain with described aptamer There is the derivant of the aptamer of identical function.
Described aptamer can be used for the test kit of preparation detection CRISP1.
Utilize the aptamer of the present invention, in can capturing in saliva in CRISP1, thus for related oral cancer Examination.Utilize the aptamer of the present invention, there is highly sensitive, low cost, the easy advantage prepared, easily preserve.The present invention has very High using value.
Detailed description of the invention
Below example facilitates a better understanding of the present invention, but does not limit the present invention.Experiment in following embodiment Method, if no special instructions, is conventional method.
Embodiment 1, the acquisition of CRISP1 albumen
CRISP1 gene shown in Genbank:EAX04350 is carried out table by the eukaryotic expression mode that this area is conventional Reach, it is thus achieved that corresponding desired polypeptides albumen.
The screening of embodiment 2 aptamer and preparation
Two ends comprise about 20 nucleotide, centre includes that the random nucleic acid library of 41 nucleotide is as follows in design:
5‘-TGGCACCTACGATCTAAGGCA(N41)GGACTACCAATGCAACGTCAC-3’；N41 represents 41 at random Nucleotide.
Being double-stranded DNA by single-stranded DNA banks amplification, product is through 2% agarose gel electrophoresis and cuts glue recovery purification；To return The double-stranded DNA received is template, and in vitro transcription goes out single stranded RNA random library, and transcription product is through PAGE purification.75 μ g RNA library warps The anti-sieve of nitrocellulose filter removes the RNA molecule being combined with film, then with 2ug CRISP1 albumen, hatches 30min for 37 DEG C, reaction Liquid filters through nitrocellulose filter, washs filter membrane；Then filter membrane is shredded, be placed in elution buffer (6mol/L carbamide, 0.55mol/L ammonium acetate, l.5mmol/L EDTA, 0.15%SDS) in boil 5min, centrifugal, take supernatant, dehydrated alcohol precipitates RNA, and be redissolved in 20 μ 1DEPC water；With RNA for template RT-PCR amplifying doulbe-chain DNA, in vitro transcription goes out RNA library and uses Screen in next round；Often in wheel screening process, RT-PCR obtains double-stranded DNA library, goes out with this double-stranded DNA for template in vitro transcription RNA aptamer storehouse, screening carries out 12 altogether and takes turns.Having obtained 15 aptamers, its sequence is respectively shown in SEQ ID NO:1-15.Tool Body sequence is as follows:
CRISP1-1:
TGGCACCTACGATCTAAGGCAATCCCATATATGTTCCACACACTCGCAACTTATCCGCTACA
GGACTACCAATGCAACGTCAC
CRISP1-2:
TGGCACCTACGATCTAAGGCATTCCGCCATAAATAAGATTCACATCACGACATCGATCACAC
GGACTACCAATGCAACGTCAC
CRISP1-3:
TGGCACCTACGATCTAAGGCACTTAATCAACATATCTCTTCTGTATTCTCTCCACGCATACA
GGACTACCAATGCAACGTCAC
CRISP1-4:
TGGCACCTACGATCTAAGGCAACGTCTCCAATCCGCACTTATAATTATGTTCTTACCTAAGA
GGACTACCAATGCAACGTCAC
CRISP1-5:
TGGCACCTACGATCTAAGGCACGCTCATCACCATCTCCTACCTATATACATCACCTTCGCCT
GGACTACCAATGCAACGTCAC
CRISP1-6:
TGGCACCTACGATCTAAGGCACATATCATCCTCCATACACGACCAACCACTCCGTCTTCACT
GGACTACCAATGCAACGTCAC
CRISP1-7:
TGGCACCTACGATCTAAGGCAAACAAACACTCTCGCACATTACCTTATTTATCAAGAATATA
GGACTACCAATGCAACGTCAC
CRISP1-8:
TGGCACCTACGATCTAAGGCACCGCTTATCTACACTAAATACAATTTCCTCCTCACCCTCCA
GGACTACCAATGCAACGTCAC
CRISP1-9:
TGGCACCTACGATCTAAGGCACACGCCTCCAATATCAACTTAATAATACACCACTAATTTCT
GGACTACCAATGCAACGTCAC
CRISP1-10:
TGGCACCTACGATCTAAGGCACACACGCCACTTATACAACAATCCAACCGCCTACCACTACT
GGACTACCAATGCAACGTCAC
CRISP1-11:
TGGCACCTACGATCTAAGGCATAGCATCACTACTCGCTATTTCCTATAATCCTAGCCTTATA
GGACTACCAATGCAACGTCAC
CRISP1-12:
TGGCACCTACGATCTAAGGCACTAGAAACTCCAACACATACACACACAGACCCGCTCCATAA
GGACTACCAATGCAACGTCAC
CRISP1-13:
TGGCACCTACGATCTAAGGCATCGCATAACGCTCCACAATATTAACATACTTCTCTTCTTAT
GGACTACCAATGCAACGTCAC
CRISP1-14:
TGGCACCTACGATCTAAGGCATCATAATATTCGCTCACTCTAATCATACATTATCTTCTTGT
GGACTACCAATGCAACGTCAC
CRISP1-15:
TGGCACCTACGATCTAAGGCAATAATATTCGCTCACTATAATCAACATTATCTTCTTGTTCT
GGACTACCAATGCAACGTCAC
The performance measurement of embodiment 3 protein binding aptamer
Aptamer taking 2.0 μ g respectively, digests lh with calf intestinal alkaline phosphatase (CIP) 37 DEG C, purification reclaims and removes phosphoric acid The RNA changed；By T4 polynucleotide kinase labelling [γ-32P] ATP in dephosphorylized RNA molecule end.10nmol radioactivity The aptamer of labelling with variable concentrations (1-200nM) CRISP137 DEG C respectively hatches 30min, and each group reactant liquor is through cellulose nitrate Element membrane filtration mistake, washs filter membrane, is dried filter membrane, and liquid scintillation counter measures the exit dose of residual on filter membrane, and same sample is parallel does two Secondary mensuration.Calculate the dissociation constant of each aptamer and destination protein.Result is as follows:
Title Dissociation constant Kd (unit nM)
CRISP1-1 9.9
CRISP1-2 9.7
CRISP1-3 9.8
CRISP1-4 9.6
CRISP1-5 9.4
CRISP1-6 9.3
CRISP1-7 9.4
CRISP1-8 9.6
CRISP1-9 9.0
CRISP1-10 9.7
CRISP1-11 9.6
CRISP1-12 9.7
CRISP1-13 9.0
CRISP1-14 8.9
CRISP1-15 8.8
PBS blank Without binding ability
Aptamer specificity analyses and stability analysis described in embodiment 4
It is respectively adopted human albumin, immune globulin, vibrio cholera VgrG3C albumen, escherichia coli outer membrane protein A, COCH albumen, CRISP1 albumen, carry out specific detection with 15 aptamers, find through binding tests, these aptamers Do not combine with these albumen, and only keep higher specificity with CRISP1 protein binding.
By described aptamer, take 0.2ug, be respectively placed in the serum of room temperature, aqueous solution, place two weeks.Pass through RT- PCR detects, and finds its Stability Analysis of Structures of placement of three weeks, is not degraded.
The diagnosis of aptamer disease described in embodiment 5
Take the salivation thing of 9 lip cancer patients and 3 normal persons, use normal saline dilution, it is thus achieved that target sample.
By 15 markd aptamers of coupling respectively with the secretions mixing 30min of 9 patients and 3 normal persons, Separated by biotin, the content of quantitative analysis CRISP1 therein albumen, found by analysis, in 9 oral cancer patients The content of CRISP1 albumen dramatically increases, and has exceeded the threshold value of regulation.Reach the diagnostic criteria of lip cancer.As can be seen here, it is examined Disconnected effect is preferable.
These are only the preferred embodiments of the present invention, be not limited to the present invention, for those skilled in the art For Yuan, all any modification, equivalent substitution and improvement etc. done within the spirit and principles in the present invention, should be included in this Within the protection domain of invention.
Sequence table
＜ 110 ＞ Chen Bo
The test kit of ＜ 120 ＞ mono-species-specific diagnosis lip cancer
〈160〉15
〈210〉1
〈211〉 83
〈212〉DNA
＜ 213 ＞ artificial sequence
〈400〉CRISP1-1
TGGCACCTACGATCTAAGGCAATCCCATATATGTTCCACACACTCGCAACTTATCCGCTACA GGACTACCAATGCAACGTCAC
〈210〉2
〈211〉 83
〈212〉DNA
＜ 213 ＞ artificial sequence
〈400〉CRISP1-2
TGGCACCTACGATCTAAGGCATTCCGCCATAAATAAGATTCACATCACGACATCGATCACAC GGACTACCAATGCAACGTCAC
〈210〉3
〈211〉 83
〈212〉DNA
＜ 213 ＞ artificial sequence
〈400〉CRISP1-3
TGGCACCTACGATCTAAGGCACTTAATCAACATATCTCTTCTGTATTCTCTCCACGCATACA GGACTACCAATGCAACGTCAC
〈210〉4
〈211〉 83
〈212〉DNA
＜ 213 ＞ artificial sequence
〈400〉CRISP1-4
TGGCACCTACGATCTAAGGCAACGTCTCCAATCCGCACTTATAATTATGTTCTTACCTAAGA GGACTACCAATGCAACGTCAC
〈210〉5
〈211〉 83
〈212〉DNA
＜ 213 ＞ artificial sequence
〈400〉CRISP1-5
TGGCACCTACGATCTAAGGCACGCTCATCACCATCTCCTACCTATATACATCACCTTCGCCT GGACTACCAATGCAACGTCAC
〈210〉6
〈211〉 83
〈212〉DNA
＜ 213 ＞ artificial sequence
〈400〉CRISP1-6
TGGCACCTACGATCTAAGGCACATATCATCCTCCATACACGACCAACCACTCCGTCTTCACT GGACTACCAATGCAACGTCAC
〈210〉7
〈211〉 83
〈212〉DNA
＜ 213 ＞ artificial sequence
〈400〉CRISP1-7
TGGCACCTACGATCTAAGGCAAACAAACACTCTCGCACATTACCTTATTTATCAAGAATATA GGACTACCAATGCAACGTCAC
〈210〉8
〈211〉 83
〈212〉DNA
＜ 213 ＞ artificial sequence
〈400〉CRISP1-8
TGGCACCTACGATCTAAGGCACCGCTTATCTACACTAAATACAATTTCCTCCTCACCCTCCA GGACTACCAATGCAACGTCAC
〈210〉9
〈211〉 83
〈212〉DNA
＜ 213 ＞ artificial sequence
〈400〉CRISP1-9
TGGCACCTACGATCTAAGGCACACGCCTCCAATATCAACTTAATAATACACCACTAATTTCT GGACTACCAATGCAACGTCAC
〈210〉10
〈211〉 83
〈212〉DNA
＜ 213 ＞ artificial sequence
〈400〉CRISP1-10
TGGCACCTACGATCTAAGGCACACACGCCACTTATACAACAATCCAACCGCCTACCACTACT GGACTACCAATGCAACGTCAC
〈210〉11
〈211〉 83
〈212〉DNA
＜ 213 ＞ artificial sequence
〈400〉CRISP1-11
TGGCACCTACGATCTAAGGCATAGCATCACTACTCGCTATTTCCTATAATCCTAGCCTTATA GGACTACCAATGCAACGTCAC
〈210〉12
〈211〉 83
〈212〉DNA
＜ 213 ＞ artificial sequence
〈400〉CRISP1-12
TGGCACCTACGATCTAAGGCACTAGAAACTCCAACACATACACACACAGACCCGCTCCATAA GGACTACCAATGCAACGTCAC
〈210〉13
〈211〉 83
〈212〉DNA
＜ 213 ＞ artificial sequence
〈400〉CRISP1-13
TGGCACCTACGATCTAAGGCATCGCATAACGCTCCACAATATTAACATACTTCTCTTCTTAT GGACTACCAATGCAACGTCAC
〈210〉14
〈211〉 83
〈212〉DNA
＜ 213 ＞ artificial sequence
〈400〉CRISP1-14
TGGCACCTACGATCTAAGGCATCATAATATTCGCTCACTCTAATCATACATTATCTTCTTGT GGACTACCAATGCAACGTCAC
〈210〉15
〈211〉 83
〈212〉DNA
＜ 213 ＞ artificial sequence
〈400〉CRISP1-15
TGGCACCTACGATCTAAGGCAATAATATTCGCTCACTATAATCAACATTATCTTCTTGTTCT GGACTACCAATGCAACGTCAC

Claims (3)

1. for a test kit for lip cancer detection, its contain can the nucleic acid that is combined with CRISP1 protein-specific of specificity suitable Body.
2. test kit as claimed in claim 1, it is characterised in that: the sequence of described aptamer such as SEQ ID No:11 institute State.
3. the method detecting lip cancer, it is characterised in that utilize the test kit described in any one of claim 1-2.
CN201610623977.8A 2015-11-15 2015-11-15 Lip cancer specificity detection kit Pending CN106053843A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610623977.8A CN106053843A (en) 2015-11-15 2015-11-15 Lip cancer specificity detection kit

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201510775706.XA CN105353126B (en) 2015-11-15 2015-11-15 A kind of test kit of lip cancer specific detection
CN201610623977.8A CN106053843A (en) 2015-11-15 2015-11-15 Lip cancer specificity detection kit

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201510775706.XA Division CN105353126B (en) 2015-11-15 2015-11-15 A kind of test kit of lip cancer specific detection

Publications (1)

Publication Number Publication Date
CN106053843A true CN106053843A (en) 2016-10-26

Family

ID=55329130

Family Applications (15)

Application Number Title Priority Date Filing Date
CN201610623978.2A Pending CN106053844A (en) 2015-11-15 2015-11-15 Lip cancer specificity detection kit
CN201610624046.XA Pending CN106018811A (en) 2015-11-15 2015-11-15 Kit for detecting specificity of lip cancer
CN201610624264.3A Pending CN106018813A (en) 2015-11-15 2015-11-15 Kit for detecting specificity of lip cancer
CN201610624182.9A Pending CN106053846A (en) 2015-11-15 2015-11-15 Lip cancer specificity detection kit
CN201610624169.3A Withdrawn CN106226533A (en) 2015-11-15 2015-11-15 A kind of test kit of lip cancer specific detection
CN201610623977.8A Pending CN106053843A (en) 2015-11-15 2015-11-15 Lip cancer specificity detection kit
CN201610624332.6A Withdrawn CN106226534A (en) 2015-11-15 2015-11-15 A kind of test kit of lip cancer specific detection
CN201610624011.6A Pending CN106018810A (en) 2015-11-15 2015-11-15 Kit for detecting specificity of lip cancer
CN201610624012.0A Pending CN106053845A (en) 2015-11-15 2015-11-15 Lip cancer specificity detection kit
CN201510775706.XA Expired - Fee Related CN105353126B (en) 2015-11-15 2015-11-15 A kind of test kit of lip cancer specific detection
CN201610623940.5A Pending CN106053842A (en) 2015-11-15 2015-11-15 Lip cancer specificity detection kit
CN201610624160.2A Withdrawn CN106226532A (en) 2015-11-15 2015-11-15 A kind of test kit of lip cancer specific detection
CN201610623980.XA Pending CN106018833A (en) 2015-11-15 2015-11-15 Kit for detecting specificity of lip cancer
CN201610624284.0A Pending CN106053847A (en) 2015-11-15 2015-11-15 Lip cancer specificity detection kit
CN201610624258.8A Pending CN106018812A (en) 2015-11-15 2015-11-15 Kit for specific detection of lip cancer

Family Applications Before (5)

Application Number Title Priority Date Filing Date
CN201610623978.2A Pending CN106053844A (en) 2015-11-15 2015-11-15 Lip cancer specificity detection kit
CN201610624046.XA Pending CN106018811A (en) 2015-11-15 2015-11-15 Kit for detecting specificity of lip cancer
CN201610624264.3A Pending CN106018813A (en) 2015-11-15 2015-11-15 Kit for detecting specificity of lip cancer
CN201610624182.9A Pending CN106053846A (en) 2015-11-15 2015-11-15 Lip cancer specificity detection kit
CN201610624169.3A Withdrawn CN106226533A (en) 2015-11-15 2015-11-15 A kind of test kit of lip cancer specific detection

Family Applications After (9)

Application Number Title Priority Date Filing Date
CN201610624332.6A Withdrawn CN106226534A (en) 2015-11-15 2015-11-15 A kind of test kit of lip cancer specific detection
CN201610624011.6A Pending CN106018810A (en) 2015-11-15 2015-11-15 Kit for detecting specificity of lip cancer
CN201610624012.0A Pending CN106053845A (en) 2015-11-15 2015-11-15 Lip cancer specificity detection kit
CN201510775706.XA Expired - Fee Related CN105353126B (en) 2015-11-15 2015-11-15 A kind of test kit of lip cancer specific detection
CN201610623940.5A Pending CN106053842A (en) 2015-11-15 2015-11-15 Lip cancer specificity detection kit
CN201610624160.2A Withdrawn CN106226532A (en) 2015-11-15 2015-11-15 A kind of test kit of lip cancer specific detection
CN201610623980.XA Pending CN106018833A (en) 2015-11-15 2015-11-15 Kit for detecting specificity of lip cancer
CN201610624284.0A Pending CN106053847A (en) 2015-11-15 2015-11-15 Lip cancer specificity detection kit
CN201610624258.8A Pending CN106018812A (en) 2015-11-15 2015-11-15 Kit for specific detection of lip cancer

Country Status (1)

Country Link
CN (15) CN106053844A (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103308691A (en) * 2013-05-22 2013-09-18 苏州市马尔泰新材料有限公司 Application of secretory protein 1 rich in cysteine in preparation of product for diagnosing cheilocarcinoma
CN104818278A (en) * 2015-04-17 2015-08-05 刘红卫 Aptamer capable of being in specific binding to TS/MDEP protein in gastric cancer cells
CN104830867A (en) * 2015-06-07 2015-08-12 杨洋 Aptamer capable of being specifically combined with DKK1 protein in cancer cells

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1931996B1 (en) * 2006-02-17 2013-11-20 Children's Medical Center Corporation Free ngal as a biomarker for cancer
EP2295975B1 (en) * 2009-09-10 2014-06-18 Bruker Daltonik GmbH Determining the expression status of human epidermal growth factor receptor 2 (HER2) in biological samples
WO2012075069A2 (en) * 2010-12-02 2012-06-07 Dana-Farber Cancer Institute, Inc. Signatures and determinants associated with cancer and methods of use thereof
CN103267863A (en) * 2013-05-22 2013-08-28 苏州市马尔泰新材料有限公司 CRISP1 (cystein-rich secretory protein 1) test paper for quickly diagnosing carcinoma of maxillary sinus
CN103308682A (en) * 2013-05-22 2013-09-18 苏州市马尔泰新材料有限公司 Kit for rapid lip cancer diagnosis
CN103278645B (en) * 2013-05-22 2015-01-28 上海市第十人民医院 Application of gold-labelled test strip for quickly diagnosing carcinoma of lip

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103308691A (en) * 2013-05-22 2013-09-18 苏州市马尔泰新材料有限公司 Application of secretory protein 1 rich in cysteine in preparation of product for diagnosing cheilocarcinoma
CN104818278A (en) * 2015-04-17 2015-08-05 刘红卫 Aptamer capable of being in specific binding to TS/MDEP protein in gastric cancer cells
CN104830867A (en) * 2015-06-07 2015-08-12 杨洋 Aptamer capable of being specifically combined with DKK1 protein in cancer cells

Also Published As

Publication number Publication date
CN106018833A (en) 2016-10-12
CN106018813A (en) 2016-10-12
CN106226534A (en) 2016-12-14
CN105353126B (en) 2016-11-02
CN106053842A (en) 2016-10-26
CN106018810A (en) 2016-10-12
CN106053847A (en) 2016-10-26
CN106018812A (en) 2016-10-12
CN106226533A (en) 2016-12-14
CN106053845A (en) 2016-10-26
CN106226532A (en) 2016-12-14
CN106053844A (en) 2016-10-26
CN105353126A (en) 2016-02-24
CN106053846A (en) 2016-10-26
CN106018811A (en) 2016-10-12

Similar Documents

Publication Publication Date Title
CN105203763B (en) A kind of test kit of oral cancer specific detection
CN105353126B (en) A kind of test kit of lip cancer specific detection
CN105842444A (en) Kit for specific detection on endometrial cancer
CN105334328B (en) Kit and method for detecting ophthalmic diseases
CN105974134A (en) Kit for detecting nasopharynx cancer and detection method of kit

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20161026

WD01 Invention patent application deemed withdrawn after publication